White House requires federal grantees to order synthetic DNA from screened suppliers

Overview

Updated 1 hour ago

Any U.S. scientist who takes federal money and orders synthetic DNA will soon have to buy it from a supplier the government has vetted. The National Policy for Nucleic Acid Synthesis Screening, released on 5 November, ends a voluntary system that has governed the industry since 2010.

Suppliers must verify who their customers are, run every order of 50 or more nucleotides through screening software verified by the National Institute of Standards and Technology, and report suspicious orders to federal authorities. The requirements phase in over 340 days, with the supplier list and mandatory purchasing deadlines falling in 2027.

Why it matters

Every federally funded lab that orders DNA will have to buy from a screened, identity-checked supplier, changing how a routine research purchase works.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

Minimum order length screened

Orders of 50 or more nucleotides fall under the policy, down from a 200-nucleotide window in earlier guidance.

340

Days to full implementation

The policy phases in from release to mandatory purchasing of benchtop equipment.

Years suppliers must keep screening records

Records and customer interactions must be produced to NIST or federal authorities on lawful request.

Conditions for an approved supplier

Verified screening, customer checks, reporting flagged orders, record retention, and cooperation with records requests.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Kevin Esvelt

Biotechnologist and biosecurity researcher, Massachusetts Institute of Technology

Supports the policy, argues its 50-nucleotide threshold leaves a gap

Drew Endy

Synthetic biology researcher, Stanford University

Describes the shift from voluntary to verified screening as a step forward

Gigi Gronvall

Immunologist and biosecurity expert, Johns Hopkins University

Calls the policy partial, points to gaps outside synthetic DNA ordering

Organizations Involved

National Institute of Standards and Technology

US federal agency

Must issue screening standards and certify the software suppliers use

The Commerce Department agency assigned to write the technical standards and test the screening tools the policy depends on.

Michigan Department of Health and Human Services

State Health Agency

Publishes the initial list of approved suppliers

The department that wrote the earlier screening guidance and now publishes which suppliers meet the policy.

International Gene Synthesis Consortium

Industry group

Members already screened orders voluntarily before the policy

An industry group whose members account for most DNA synthesis worldwide and had agreed to screen orders on their own.

Federal Bureau of Investigation (FBI)

US federal law enforcement agency

Named recipient for reports of flagged DNA orders

The agency suppliers and screening tools must notify when an order raises unresolved concerns.

Timeline

2010 November 2026

4 events Latest: 4 days ago

Tap a bar to jump to that date

November 2026
White House releases nucleic acid screening policy
Latest Policy

Federal grantees must buy synthetic DNA and benchtop synthesizers only from suppliers meeting five conditions.
4 days ago
March 2026
Updated federal framework still pending
Policy

An update to the screening framework, including possible coverage of non-federally funded buyers, had not been issued.
March 2026
2023
Federal guidance narrows screening window to 50 nucleotides
Policy

The health department's framework lowers the recommended threshold from 200 nucleotides to catch shorter risky fragments.
2023
2010
U.S. issues voluntary DNA screening guidelines
Policy

Companies are recommended, not required, to vet customers and screen orders for dangerous sequences.
2010

Scenarios

Supplier list lands on schedule and grantees switch by summer 2027

Likely Resolves by Aug 31, 2027

Discussed by: Policy implementation schedule; Drew Endy and Kevin Esvelt both treat the timeline as achievable if funded

NIST issues screening standards by early February 2027, begins certifying tools shortly after, and HHS publishes the first Adherent Supplier list in April. Federally funded labs move their orders to listed suppliers before the July 2027 deadline, and the benchtop equipment deadline follows in October. Compliance is quiet because most large suppliers already screened orders voluntarily.

Verification backlog stalls the rollout past its deadlines

Possible Resolves by Oct 11, 2027

Discussed by: Drew Endy and Kevin Esvelt, both quoted questioning NIST's funding and capacity

NIST is asked to write standards, build testing protocols, and certify screening tools without a dedicated appropriation. If certification lags, HHS has no verified tools to anchor a supplier list, and grantees face a deadline they cannot meet. Agencies then extend deadlines or issue interim guidance.

Policy amended to cover DNA fragments shorter than 50 nucleotides

Unlikely Resolves by Oct 11, 2027

Discussed by: Kevin Esvelt, who says he has built a 30-nucleotide screening algorithm

Critics argue a buyer can split a dangerous sequence into fragments below the cutoff and order them from different suppliers. If that gap gets attention, NIST's screening standards or a revised policy could lower the threshold. The trigger would be a specific demonstration or an agency review, not a general complaint.

Screening requirement extends to buyers without federal funding

Uncertain Resolves by End of 2028

Discussed by: Kevin Esvelt expects companies to apply screening to all customers; Gigi Gronvall notes the policy covers only the U.S.

The policy binds only federal grantees, but suppliers that build one screening pipeline may run every order through it. A formal extension would need a rule or statute covering non-federally funded buyers, which the pending framework update had left open.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

February 1975

Asilomar conference on recombinant DNA (1975)

Biologists met at Asilomar in California after scientists voluntarily paused certain recombinant DNA experiments. They produced safety recommendations that the National Institutes of Health later turned into binding rules for federally funded research.

Then

Research resumed under containment levels matched to the risk of each experiment.

Now

Set the pattern of scientists writing safety rules first and federal funders enforcing them later.

Why this matters now

The DNA synthesis policy follows the same sequence: an industry that screened orders voluntarily for 16 years now faces federal conditions on the same practice.

2010

Voluntary DNA synthesis screening guidelines (2010)

The U.S. government recommended that companies making synthetic double-stranded DNA vet their customers and check orders for sequences that could encode toxins or pathogens. Compliance was optional, though members of the main industry group agreed to follow it.

Then

Most large suppliers screened orders, while others were not bound to.

Now

The arrangement held for 16 years without an enforcement mechanism or a government-verified list of compliant suppliers.

Why this matters now

The 2026 policy keeps the same screening idea but makes it a purchasing condition, with government-verified tools and a published supplier list.

2023

HHS lowers the screening threshold to 50 nucleotides (2023)

The Department of Health and Human Services replaced a 200-nucleotide screening window with a 50-nucleotide baseline, on the reasoning that shorter fragments are easier to assemble into something dangerous.

Then

Suppliers following the framework began screening far more orders.

Now

The 50-nucleotide figure became the reference point the 2026 policy adopted.

Why this matters now

The new policy inherits the 50-nucleotide threshold, which is exactly the number critics now say is too high.